0000950170-23-067358.txt : 20231201 0000950170-23-067358.hdr.sgml : 20231201 20231201163005 ACCESSION NUMBER: 0000950170-23-067358 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231129 FILED AS OF DATE: 20231201 DATE AS OF CHANGE: 20231201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dorval Allison CENTRAL INDEX KEY: 0001625110 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 231459951 MAIL ADDRESS: STREET 1: C/O INSULET CORPORATION STREET 2: 600 TECHNOLOGY PARK DRIVE, SUITE 200 CITY: BILLERICA STATE: MA ZIP: 01821 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 4 1 ownership.xml 4 X0508 4 2023-11-29 0001840574 Verve Therapeutics, Inc. VERV 0001625110 Dorval Allison C/O VERVE THERAPEUTICS 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215 false true false false Chief Financial Officer false Common Stock 2023-11-29 4 M false 1875 A 4614 D Common Stock 2023-11-29 4 S false 554 11.45 D 4060 D Restricted Stock Units 2023-11-29 4 M false 1875 0 D Common Stock 1875 3750 D Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Includes 553 shares of the Company's common stock acquired in 2023 under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on December 9, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. On November 29, 2021, the reporting person was granted 7,500 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on November 29, 2022 and the remainder vesting in equal annual installments until November 29, 2025. /s/ Andrew Ashe, as Attorney-in-Fact for Allison Dorval 2023-12-01